Ultrasound Molecular Imaging for the Guidance of Ultrasound-Triggered Release of Liposomal Doxorubicin and Its Treatment Monitoring in an Orthotopic Prostatic Tumor Model in Rat
| Autor: | Frédéric Padilla, Thierry Bettinger, Alexandre Helbert, Mathew A. Von Wronski, Isabelle Tardy, Jean-Louis Mestas, Cyril Lafon, Jean-Marc Hyvelin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Drug Acoustics and Ultrasonics media_common.quotation_subject Confocal Biophysics Polyethylene Glycols medicine Animals Humans Radiology Nuclear Medicine and imaging Doxorubicin media_common Liposome Radiological and Ultrasound Technology Chemistry business.industry Ultrasound Prostatic Neoplasms Ultrasound molecular imaging Kinase insert domain receptor Molecular Imaging Rats Liposomes business Treatment monitoring medicine.drug Biomedical engineering |
| Zdroj: | Ultrasound in Medicine & Biology. 47:3420-3434 |
| ISSN: | 0301-5629 |
| DOI: | 10.1016/j.ultrasmedbio.2021.07.022 |
| Popis: | Liposome encapsulation of drugs is an interesting approach in cancer therapy to specifically release the encapsulated drug at the desired treatment site. In addition to thermo-, pH-, light-, enzyme- or redox-responsive liposomes, which have had promising results in (pre-) clinical studies, ultrasound-triggered sonosensitive liposomes represent an exciting alternative to locally trigger the release from these cargos. Localized drug release requires precise tumor visualization to produce a targeted and ultrasound stimulus. We used ultrasound molecular imaging (USMI) with BR55, a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasound contrast agent, to guide ultrasound-triggered release of sonosensitive liposomes encapsulating doxorubicin (L-DXR) in an orthotopic prostatic rodent tumor model. Forty-eight hours after L-DXR injection, local release of doxorubicin was triggered with a confocal ultrasound device with two focused transducers, 1.1-MHz center frequency, and peak positive and negative pressures of 20.5 and 13 MPa at focus. Tumor size decreased by 20% in 2 wk with L-DXR alone (n = 9) and by 70% after treatment with L-DXR and confocal ultrasound (n = 7) (p0.01). The effect of doxorubicin on perfusion/vascularity and VEGFR2 expression was evaluated by USMI and immunohistochemistry of CD31 and VEGFR2 and did not reveal differences in perfusion or VEGFR2 expression in the absence or after the triggered release of liposomes. USMI can provide precise guidance for ultrasound-triggered release of liposomal doxorubicin mediated by a confocal ultrasound device; moreover, the combination of B-mode imaging and USMI can help to follow the response of the tumor to the therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|